Intraorgan metastasis of a primary cancer within the organ of origin, such as intrahepatic metastasis of hepatocellular carcinoma, is one of the key features for clinicopathologic staging of the cancer. Pancreatic intraglandular metastasis (P-IM) of pancreatic ductal carcinoma (PDC) is encountered occasionally but has not yet been evaluated. The aim of this study was to investigate the clinicopathologic characteristics and prognostic value of P-IM in patients with PDC. The histopathologic features of 393 consecutive patients with PDC who had undergone pancreatic resection at the National Cancer Center Hospital, Tokyo, between 2003 and 2010 were reviewed. For the purposes of the study, P-IM was defined as an independent tumor showing histopathologic features similar to those of the primary one. Twenty-six cases of P-IM were identified in 21 (5.3%) of the reviewed patients. The incidence of P-IM at each stage of the TNM classification was 0% (0/7) at stage IA, 17% (1/6) at stage IB, 5% (5/92) at stage IIA, 4% (11/252) at stage IIB, 0% (0/1) at stage III, and 11% (4/35) at stage IV. Univariate survival analysis showed that both overall survival and disease-free survival for patients with P-IM were significantly shorter than for those without P-IM (P < 0.001 and P = 0.019, respectively). Multivariate survival analysis showed that P-IM was significantly correlated with shorter overall survival (P = 0.002; hazard ratio = 2.239; 95% confidence interval: 1.328-3.773). Our findings suggest that the presence of P-IM in patients with PDC is an independent prognosticator and may represent aggressive tumor behavior. FIGURE 1. A, Representative case of P-IM with the primary tumor (case 4). A, Cut surface of a formalin-fixed specimen. The specimen resected by distal pancreatectomy was cut sagittally into serial slices of 5 mm thickness, and each of the sections are lined in order from the pancreatic body to the tail from the left to lower right of the figure. Three lesions of P-IM (lower column, red circle indicated by arrowheads) are separated from a primary ductal adenocarcinoma of the pancreatic body (white arrows). B and C, Loupe view of the primary tumor (B) and P-IM (C). (B) and (C) correspond to the rectangle in (A), respectively. D and E, Histologic features of the primary tumor (D) and P-IM (E). Poorly differentiated adenocarcinoma infiltrated into the pancreatic parenchyma with a marked desmoplastic reaction. Similar features are evident in both the primary tumor and the P-IM. (D) and (E) correspond to the rectangles in (B) and (C), respectively. Black arrows indicate the P-IM in (E). (D) and (E) are low-power views, and insets in (D) and (E) are high-power views.
P ancreatic cancer is the fourth and fifth leading cause of cancer death in the United States 1 and Japan, 2 respectively. Most patients with pancreatic ductal carcinoma (PDC) present late with locoregional advanced disease or metastatic dissemination, and the overall 5-year survival rate for such patients is <5%. 1 Even for patients whose tumors are resectable and who receive adjuvant chemotherapy, the 5-year survival rate is still as low as 20%. 3 This is partly because of a high incidence of subclinical metastasis, which is not detectable by radiologic imaging, at the time of diagnosis and surgery.
Multiplicity of a malignant tumor in any organ is caused by intraorgan metastasis and/or multiple primary tumors. A malignant tumor with intraorgan metastasis is likely to be at an advanced stage. For example, in lung cancer, an additional tumor nodule with a histologic appearance identical to that of the dominant, primary tumor is regarded as intrapulmonary metastasis, which indicates poorer prognosis and is a determinant of the T factor and M factor in the Union for International Cancer Control (UICC) TNM classification. 4 Likewise, liver cancer with intrahepatic metastasis is classified under multiple tumors and assigned a higher T factor. 4 Among patients with hepatocellular carcinoma (HCC), it has been reported that those with intrahepatic metastasis have significantly poorer survival than those with multicentric occurrence. 5 Sometimes such additional tumor nodules in the pancreas are revealed by histopathologic examination in cases of PDC, a feature known as "pancreatic intraglandular metastasis" (P-IM). 6 Similar to intrahepatic metastasis of HCC and intrapulmonary metastasis of lung cancer, P-IM is assumed to be of clinicopathologic importance in patients with PDC. However, no study has yet assessed the characteristics and clinicopathologic significance of P-IM, and its incidence, pathogenesis, and impact on prognosis remain unknown. The aim of the present study was to investigate the clinicopathologic characteristics and prognostic impact of P-IM, for which purpose we reviewed the histopathologic features of 393 consecutive cases of PDC with reference to the corresponding clinicopathologic data.
MATERIALS AND METHODS

Study Population
Clinical and pathologic data were obtained through a detailed retrospective review of the medical records of all 393 consecutive patients with PDC who had undergone initial surgical resection between January 2003 and December 2010 at the National Cancer Center Hospital, Japan. None of the patients had received any previous therapy. The surgical procedures for pancreatic resection comprised 258 pancreatoduodenectomies with or without resection of the pylorus ring, 117 distal pancreatectomies, and 18 total pancreatectomies; regional lymph node dissection was performed in all cases. All the patients included in this study underwent macroscopic curative resection, which was defined as the macroscopic removal of all gross tumors without liver metastases, macroscopic peritoneal dissemination, bulky lymph node involvement, or apparent tumor invasion around the common hepatic or superior mesenteric arteries. Peritoneal washing cytology was routinely performed just after laparotomy, although positive peritoneal cytology was not regarded as a contraindication for surgery. Ninety-three patients (24%) received intraoperative radiotherapy. All of the cases were conventional PDC; adenocarcinomas originating in intraductal papillary mucinous neoplasms (IPMNs) or mucinous cystic neoplasms were excluded, as were secondary tumors and postneoadjuvant cases. Tumors were staged according to the UICC TNM classification 4 as follows: stage IA (n = 7, 1.8%), IB (n = 6, 1.5%), IIA (n = 92, 23.4%), IIB (n = 252, 64.1%), III (n = 1, 0.3%), and IV (n = 35, 8.9%). One patient with stage III disease had PDC involving the celiac artery and underwent distal pancreatectomy with celiac axis resection. All patients with stage IV disease were diagnosed on the basis of para-aortic lymph node involvement. Patients were closely followed up every 1 to 2 months during the first year after surgery. Each follow-up visit included a physical examination, blood chemistry tests, and measurement of serum carbohydrate yClassified as presence ( +) or absence (À) of tumor invasion. ly indicates lymphatic invasion; v, venous invasion; ne, intrapancreatic neural invasion.
antigen 19-9 (CA19-9) and carcinoembryonic antigen. Ultrasonography and enhanced computed tomography were performed every 3 months. Recurrence was diagnosed when a new local or distant metastatic lesion was found on imaging studies or an increase in tumor marker levels with deterioration of the patient's general condition was recog-nized. The follow-up period was calculated from the date of surgery to the last day of follow-up. The median follow-up period was 20.5 (1.1 to 100.8) months for the patients overall: 164 patients (41.7%) were alive, 197 (50.1%) died because of pancreatic cancer, and 32 (8.2%) died of other causes. During the study period, adjuvant chemotherapy was not performed routinely. A total of 124 patients received adjuvant chemotherapy in a randomized clinical trial setting or at the discretion of the attending physician. This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo. Written informed consent was obtained from all participants involved in this study, and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.
Pathologic Examination
All of the ductal carcinomas were reexamined pathologically and classified according to the World Health Organization classification, 7 the UICC TNM classification, 4 and the Japan Pancreas Society Classification of Pancreatic Carcinoma. 8 Surgically resected specimens were fixed in 10% formalin and cut into serial slices 5 mm thick, horizontally in the pancreas head, and sagittally in the pancreas body and tail. All of these sections were then subjected to detailed pathologic examination after staining with hematoxylin and eosin. The following histopathologic variables were evaluated according to the Japan Pancreas Society classification 8 : tumor margin status, nerve plexus invasion, and lymphatic, venous, and intrapancreatic neural invasion. The grading of the latter 4 factors is as follows: 0, no invasion; 1, slight invasion; 2, moderate invasion; and 3, marked invasion.
For evaluation of venous invasion and intraductal tumor spread, tissue sections were stained for elastic fibers. To investigate lymphatic invasion, we also performed immunohistochemical analysis for podoplanin, which is a specific marker of lymphatic vessels. Immunohistochemical analysis was performed on formalinfixed, paraffin-embedded tissue sections as mentioned previously, 9 using an antibody against podoplanin (D2-40, 1:100; Dako, Glostrup, Denmark). The size of the P-IM and its distance from the primary tumor to the P-IM were measured.
Pancreatic intraepithelial neoplasm (PanIN)-3 is sometimes difficult to distinguish from intraepithelial spread of invasive carcinoma in pancreatic ducts or ductules. To detect multicentric tumors with certainty, we defined solitary PanIN-3 as a PanIN-3 lesion separated from any invasive carcinoma and located within the pancreas. In each case, the size of the lesion and its distance from the dominant, primary invasive carcinoma, were measured.
Criteria for Identifying P-IM
We defined P-IM with reference to the definitions of intrahepatic metastasis of HCC 10 and intrapulmonary metastasis of lung cancer. 11 When multiple invasive PDCs were detected in the specimen, we defined as P-IM those additional tumors that met all of the following conditions: (i) located within the pancreatic parenchyma and separated from the dominant, primary tumor by a distance of 5 mm or more; (ii) showing histologic appearances identical to that of the dominant, primary tumor; (iii) differentiated to the same degree or less as the dominant, primary tumor; (iv) unaccompanied by premalignant lesions of PDC such as PanIN and IPMN, implying that the tumors might be other primaries arising through multicentric carcinogenesis. To confirm discontinuity between P-IM and the premalignant lesions, we considered an invasive lesion to be separated from PanIN-3 or noninvasive IPMN with high-grade dysplasia by a distance of 5 mm or more. Intraepithelial spread of the invasive carcinoma in pancreatic ducts or ductules, that is, so-called cancerization of ducts, was also excluded. Because at our institution resected specimens are cut into serial slices of 5 mm thickness, a distance of 5 mm from the main lesion was used to confirm discontinuity. A representative case of P-IM is shown in Figure 1 .
Statistical Analysis
w 2 analysis or the Fisher exact test was used to compare categorical data. The postoperative overall survival (OS) rate and disease-free survival (DFS) rate were calculated by the Kaplan-Meier method. Univariate analysis was performed for prognostic factors using the log rank test. The factors found to be significant by univariate analysis were subjected to multivariate analysis using the Cox proportional hazards model (backward elimination method). Differences at P < 0.05 were considered statistically significant. Statistical analyses were performed using the Statistical Package for the Social Sciences (version 20.0; SPSS Inc., Chicago, IL).
RESULTS
Characteristics of P-IM
Twenty-six P-IMs were identified in 21 (5.3%) of the 393 patients. None of the P-IMs had been detected by preoperative radiologic imaging or intraoperative examination using ultrasonography and was identified postoperatively for the first time by microscopic examination. Table 1 shows the pathologic features of the P-IMs and the primary tumors. The incidence of P-IM at each stages of the TNM classification was 0% (0/7) at stage IA, 17% (1/6) at stage IB, 5% (5/92) at stage IIA, 4% (11/252) at stage IIB, 0% (0/1) at stage III, and 11% (4/35) at stage IV. One patient had 3 P-IM lesions, 3 patients had 2, and the other patients had 1 P-IM lesion each. The maximum size of the P-IM ranged from 1 to 10 mm with a median of 3.0 mm and an average of 3.4 mm, and the distance from the primary tumor to the P-IM ranged from 5 to 25 mm with a median of 10.5 mm and an average of 12.3 mm. Lymphatic invasion, venous invasion, and intrapancreatic neural invasion within the P-IM were detected in 35% (9/26), 62% (16/26), and 12% (3/26) of the lesions, respectively.
Forty-one of the solitary PanIN-3 lesions were identified in 24 (6.1%) of the patients. One solitary Pan-IN-3 lesion was detected in 18 of the patients, 2 lesions in 2, 3 lesions in 2, 5 lesions in 1, and 8 lesions in 1. The average, median, and range of lesion size were 4.58, 2, and <1 to 20 mm, respectively. The average, mean, and range of distance between the solitary PanIN-3 and the dominant invasive carcinoma was 19.5, 15, and 5 to 60 mm, respectively. One case involving 2 overt invasive primary PDCs was found at surgery. One patient (case 11, Table 2 shows the correlation of P-IM with clinicopathologic characteristics of the patients with PDC. No significant relationship was found.
Correlation of P-IM With Clinicopathologic Parameters
Prognostic Significance of the Presence of P-IM
The median survival time for patients having PDC with and without P-IM was 16 and 29 months, respectively. The 1-year survival rates for patients having PDC with and without P-IM were 59% and 83%, the 2-year rates were 18% and 57%, and the 5-year rates were 0% and 27%, respectively.
Univariate survival analysis demonstrated an association between the presence of P-IM and shorter OS [P < 0.001; hazard ratio (HR) = 2.427; 95% confidence interval (CI): 1.453-4.065] and DFS (P = 0.019; HR = 1.762; 95% CI: 1.089-2.850) ( Figs. 2A, B) . For stages IA/ IB/IIA and stage IIB, OS for patients with P-IM was significantly shorter than for those without P-IM (P = 0.025 and 0.019, respectively) ( Fig. 3) . All the recurrences (n = 18) in patients having P-IM involved peritoneal dissemination or distant metastasis, rather than local recurrence in the remnant pancreas.
Multivariate Cox regression analysis showed that P-IM (P = 0.002; HR = 2.239; 95% CI: 1.328-3.773), tumor size, pathologic node status, histologic grade, intrapancreatic neural invasion, peritoneal cytology, and adjuvant chemotherapy were independent predictors of OS and that preoperative CA 19-9 level, tumor size, pathologic node status, pathologic metastasis status, histologic grade, venous invasion, intrapancreatic neural invasion, and peritoneal cytology were independent predictors of DFS (Table 3 ). In addition, the relationship between P-IM size and survival was analyzed among the patients with P-IM, but no significant correlation was found. Similarly, there was no significant correlation between survival and the distance from the primary tumor to P-IM.
There were no significant differences in the proportions of patients undergoing intraoperative radiotherapy and adjuvant chemotherapy between those with P-IM and those without P-IM. Four (19%) of 21 patients with P-IM underwent intraoperative radiotherapy, whereas 89 (24%) of 372 patients without P-IM did so (P = 0.609). Nine (43%) of 21 patients with P-IM underwent adjuvant chemotherapy, whereas 115 (31%) of 372 patients without P-IM did so (P = 0.252). In addition, among the patients with P-IM, there was no significant difference in OS and DFS between those who underwent intraoperative radiotherapy and those who did not, as well as between those who underwent adjuvant chemotherapy and those who did not.
DISCUSSION
When multiple tumors are detected in a single organ in the absence of any primary tumors in other organs, 2 possibilities can be considered. One is a primary tumor with intraorgan metastatic lesions, and the other is the development of multiple primary tumors in the organ. Although some types of tumor often show intraorgan metastasis, details of its clinicopathologic characteristics have been investigated only for lung cancer and HCC. Such studies have revealed that patients with intraorgan metastases have poorer prognosis, [12] [13] [14] and the presence of intraorgan metastasis has been used as one of the critical factors for estimation of disease stage. 4, 10 However, no reported study has yet assessed intraglandular metastasis in patients with PDC. In the present study, we defined P-IM in patients with PDC and evaluated its characteristics and prognostic significance.
We found that P-IM was a prognostic factor indicative of shorter OS (P = 0.002; HR = 2.239; 95% CI: 1.328-3.773) in patients with PDC (Table 3) . P-IM was found not only at an advanced disease stage, but also at relatively early stages, the incidence of P-IM being 17% (1/6) at stage IB, 5% (5/92) at stage IIA, 4% (11/252) at stage IIB, and 11% (4/35) at stage IV (Table 1) . Moreover, the patients in stages IA/IB/IIA and stage IIB with P-IM had significantly shorter survival than those without (Fig. 3) . The outcome of patients with P-IM at stages IIB and IV was dismal, and among them, no patient surviving for >3 years has yet been confirmed. These findings suggest that PDC with P-IM has an aggressive nature. P-IMs were found in 21 (5.3%) of the 393 cases of PDC we studied; 24 (6.1%) of the cases involved solitary PanIN-3. In our series, multiple tumors other than the dominant, primary invasive tumor were P-IM or solitary PanIN-3, showing almost the same incidence. The in-cidence of P-IM in this study may have been underestimated for 2 reasons. One was that P-IM located within 5 mm from the primary tumor was excluded on the basis of our criteria, because continuity between the primary tumor and P-IM could not be assessed with certainty. The other was that most of the surgical procedures used were not total pancreatectomy but pancreaticoduodenectomy or distal pancreatectomy, meaning that any P-IM located in the remnant pancreas could not be assessed. Several studies have reported that the incidence of multiple pancreatic cancers in resected specimens ranges from 5% to 20%. [15] [16] [17] However, they did not mention whether the entire specimen was examined histopathologically, whether the multiple tumors were invasive, or whether the multiple tumors were P-IM or multicentric primary tumors.
The present study has provided some insight into how P-IM forms. For intrapulmonary metastasis of lung cancer, 3 possible mechanisms have been postulated: tumor cells spread through the lymphatic vessels, through blood vessels, or through the airway. 12 Intrahepatic metastasis of HCC is thought to develop through tumor cell dispersal through the portal vein or systemic circulation. 13, 14 Two routes for the formation of P-IM are possible: lymphatic and venous. PDC can spread through both of these 2 routes to form P-IM, as venous and lymphatic invasions in the area of P-IM were observed in 62% and 35% of cases with P-IM, respectively.
In conclusion, our findings indicate that the presence of P-IM in patients with PDC is an independent prognosticator and could represent aggressive tumor behavior.
